New Three-Drug attack on tough breast cancer
NCT ID NCT05286437
Summary
This study is testing a combination of three drugs—lenvatinib, pembrolizumab, and letrozole—for people with advanced breast cancer that is hormone-positive and has stopped responding to standard hormone treatments. The goal is to see if this new combination can shrink tumors and control the cancer's growth. The study will enroll about 40 participants to measure how well the treatment works and how long the benefits last.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Centre Singapore
RECRUITINGSingapore, 169610, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.